Eyenuk secures $26 million in Series A funding

Fact checked byChristine Klimanskis, ELS

Eyenuk has secured $26 million in a Series A financing round, bringing the company’s total funding to more than $43 million.

Eyenuk plans to use the funds to expand its AI product platform to include more disease indications and care coordination, as well as to accelerate global commercialization of the platform. The EyeArt AI system received FDA clearance in 2020 for diabetic retinopathy screening.

Money behind eyeglasses — Eyenuk has secured $26 million in a Series A financing round, bringing the company’s total funding to more than $43 million.
*Source: Adobe stock*

AXA IM Alts led the funding round, joined by T&W Medical A/S, A&C Foelsgaard Alternativer ApS, Kendall Capital Partners and KOFA Healthcare.

“Our Series A fundraise validates the strong market performance of the EyeArt system and provides us with critical resources as we expand our platform capabilities this year to include solutions for detecting additional diseases,” Kaushal Solanki, PhD, Eyenuk CEO and founder, said in a press release.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Eyenuk secures $26 million in Series A funding

Related Content